# Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

> **NCT01946438** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 208 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),
- **BIOLOGICAL:** Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),
- **BIOLOGICAL:** Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),
- **BIOLOGICAL:** Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)

## Key facts

- **NCT ID:** NCT01946438
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2013-12
- **Final completion:** 2014-07
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01946438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01946438, "Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01946438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*